Blood transfusion and iatrogenic risks in Mexico city: anti-Trypanosoma cruzi seroprevalence in 43,048 blood donors, evaluation of parasitemia, and electrocardiogram findings in seropositive

dc.contributor.authorNidia Hernández-Becerril
dc.contributor.authorAna María Mejía‐Jaramillo
dc.contributor.authorMartha A. Ballinas‐Verdugo
dc.contributor.authorVerónica Garza-Murillo
dc.contributor.authorElsa Manilla-Toquero
dc.contributor.authorRuth López
dc.contributor.authorS Trevethan
dc.contributor.authorManuel Cárdenas
dc.contributor.authorPedro A. Reyes
dc.contributor.authorKenji Hirayama
dc.coverage.spatialBolivia
dc.date.accessioned2026-03-22T14:31:35Z
dc.date.available2026-03-22T14:31:35Z
dc.date.issued2005
dc.descriptionCitaciones: 37
dc.description.abstractIatrogenous transmission of Trypanosoma cruzi by blood transfusion was suggested as a potential risk by Pellegrino (1949). Seropositive blood donors in Mexico were first reported in 1978, however, limited information is available due to small sampling, the use of heterogeneous serologic assays, and geographically limited studies. A wide survey carried out in 18 out of the 32 states of Mexico, showed a national mean of 1.6% seropositive among 64,969 donors, ranging from 0.2 to 2.8%. In the present study, we have screened 43,048 voluntary blood donors in a period of five years at the Instituto Nacional de Cardiología I. Chávez, a concentration hospital located in Mexico city which serves mainly the metropolitan area and accepts from all over the country. Standardized ELISA and IIF were used to identify seropositive individuals in addition to hemoculture, PCR and standard 12 lead ECG tests that were applied to a group of seropositive patients (29/161). The result showed a seropositivity of 0.37% (161/43,048). From the group of seropositive individuals 40% (12/29) were potential carriers of T. cruzi at the donation time and 5/29 had subclinical ECG abnormalities. Parasitological tests performed in 70 erythrocyte and platelet fractions from seropositive units (70/161) showed negative results. Our findings strongly support T. cruzi screening in the transfusion medicine practice and identify subclinical heart disease among seropositive blood donors.
dc.identifier.doi10.1590/s0074-02762005000200002
dc.identifier.urihttps://doi.org/10.1590/s0074-02762005000200002
dc.identifier.urihttps://andeanlibrary.org/handle/123456789/47026
dc.language.isoen
dc.publisherInstituto Oswaldo Cruz, Ministério da Saúde
dc.relation.ispartofMemórias do Instituto Oswaldo Cruz
dc.sourceInstituto Nacional de Cardiologia
dc.subjectChagas disease
dc.subjectMedicine
dc.subjectTrypanosoma cruzi
dc.subjectSubclinical infection
dc.subjectSeroprevalence
dc.subjectTransfusion medicine
dc.subjectParasitemia
dc.subjectSerology
dc.subjectBlood transfusion
dc.subjectInternal medicine
dc.titleBlood transfusion and iatrogenic risks in Mexico city: anti-Trypanosoma cruzi seroprevalence in 43,048 blood donors, evaluation of parasitemia, and electrocardiogram findings in seropositive
dc.typearticle

Files